Investigational drug · Phase 3
Bemnifosbuvir-Ruzasvir
Also called: BEM, RZR
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for HEPATITIS C VIRUS CHRONIC INFECTION, Hepatitis C, Chronic, Hepatitis C Virus Infection.
Phase 3Last checked: Nov 20, 2026Latest source record: Oct 29, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
11
Any phase or sponsor naming "Bemnifosbuvir-Ruzasvir"
First trial start
2025
Apr 7, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Bemnifosbuvir-Ruzasvir", any sponsor or status.
Conditions studied
As listed on its trial records.
- HEPATITIS C VIRUS CHRONIC INFECTION
- Hepatitis C, Chronic
- Hepatitis C Virus Infection
- Hepatitis C
Approved drugs for the same conditions: Hepatitis C · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "Bemnifosbuvir-Ruzasvir" as an intervention, largest first.
- C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCVPivotal-lookingCompleted
Atea Pharmaceuticals, Inc.Industry
NCT06868264 · 940 participants · Start Apr 7, 2025 · Primary completion Jun 18, 2026
Drug: Bemnifosbuvir-Ruzasvir (BEM/RZR); Sofosbuvir-Velpatasvir (SOF/VEL) · For: HEPATITIS C VIRUS CHRONIC INFECTION
Sites: Birmingham, Alabama; Dothan, Alabama; Chandler, Arizona · 105 sites in all
- C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCVPivotal-lookingActive, not recruiting
Atea Pharmaceuticals, Inc.Industry
NCT07037277 · 880 participants (planned) · Start Jun 2, 2025 · Primary completion Dec 2026
Drug: Bemnifosbuvir-Ruzasvir; Sofosbuvir-Velpatasvir · For: HEPATITIS C VIRUS CHRONIC INFECTION; Hepatitis C, Chronic; Hepatitis C Virus Infection and 1 more
Sites: Cairo, Egypt; Nice, France; Strasbourg, France · 107 sites in all
Atea Pharmaceuticals, Inc.Industry
NCT05904470 · 275 participants · Start May 30, 2023 · Primary completion Dec 9, 2024
Drug: Bemnifosbuvir; Ruzasvir · For: Chronic Hepatitis C Virus; Hepatitis C, Chronic; Hepatitis C and 2 more
Sites: San Antonio, Texas; Manaus, Brazil; Salvador, Brazil · 51 sites in all
Atea Pharmaceuticals, Inc.Industry
NCT06204679 · 42 participants · Start Dec 14, 2023 · Primary completion Aug 25, 2024
Drug: Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fasting conditions; Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fed conditions and 1 more · For: Healthy Volunteer Study
Sites: Cypress, California
- Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Digoxin and RosuvastatinCompleted
Atea Pharmaceuticals, Inc.Industry
NCT06921941 · 38 participants · Start Apr 8, 2025 · Primary completion Jul 2, 2025
Drug: Digoxin vs Digoxin + BEM/RZR vs Digoxin + 2h BEM/RZR; Rosuvastatin vs Rosuvastatin + BEM/RZR vs Rosuvastatin + 2h BEM/RZR · For: Healthy Volunteer Study
Sites: Québec, Canada
Atea Pharmaceuticals, Inc.Industry
NCT05731843 · 32 participants · Start Jan 30, 2023 · Primary completion Mar 15, 2023
Drug: Cohort 1 BEM + Ruzasvir; Cohort 2 Ruzasvir + BEM · For: Healthy Volunteer Study
Sites: Québec, Canada
Atea Pharmaceuticals, Inc.Industry
NCT07314346 · 30 participants · Start Jan 7, 2025 · Primary completion Jul 23, 2026
Drug: Buprenorphine/Naloxone + BEM/RZR; Methadone +BEM/RZR · For: Healthy Volunteer Study
Sites: Hollywood, Florida; Overland Park, Kansas; Marlton, New Jersey
Atea Pharmaceuticals, Inc.Industry
NCT06911320 · 28 participants · Start Apr 9, 2025 · Primary completion Apr 30, 2026
Drug: Bemnifosbuvir (BEM)/Ruzasvir (RZR) as a fixed-dose combination · For: Healthy Volunteer Study; Hepatic Impairment; Renal Impairment
Sites: Orlando, Florida; Tampa, Florida
Atea Pharmaceuticals, Inc.Industry
NCT06356194 · 28 participants · Start Apr 15, 2024 · Primary completion May 30, 2024
Drug: Cohort 1: Days 1-7 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered. Days 8-17 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered + Biktarvy (BIK). Days 18-24 BIK; Cohort 2: Days 1-10 Biktarvy (BIK). Days 11-17 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered + Biktarvy (BIK). Days 18-24 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered. · For: Healthy Volunteer Study
Sites: Québec, Canada
Atea Pharmaceuticals, Inc.Industry
NCT07272889 · 24 participants · Start Dec 4, 2025 · Primary completion Feb 17, 2026
Drug: Ethinyl Estradioll/Levonorgestrel (EE/LNG); Bemnifosbuvir/Ruzasvir (BEM/RZR) and 1 more · For: Healthy Volunteer Study
Sites: Québec, Canada
Newest research
PubMed records naming it or its code names, newest first.
- Robustness of MEG source imaging in pediatric patients with surgical cavities: A case series.
Hill E, Moreau JT, Minato E, et al. · Neuroimage Rep 2026
- Design, fabrication and measurement of a force-balanced strong gradient magnetic field assembly for a cryogen-free 7 T / 160 mm MRI superconducting magnet.
Liu Z, Wang W, Wu H, et al. · Magn Reson Imaging 2026
- Self-Powered Electronics-Free Wearable Disposable Electrotherapy (WDE) Platform for Accelerated Wound Healing.
Koochesfahani MB, Donnery K, Kumar AS, et al. · Adv Sci (Weinh) 2026
- Accurate Hippocampal Electric Field Modeling for Electroconvulsive Therapy: Numerical Accuracy and Convergence.
Noetscher GM, Drumm D, Neufeld E, et al. · bioRxiv 2026
- Efficient biosynthesis of levan using recombinant levansucrase and preservation efficacy of edible composite films.
Luo J, Wang B, Tian G, et al. · J Sci Food Agric 2026
- A Proof of Concept for Rapid Evaluation of Urban Climate Adaptations Using Simplified Simulations over an Indian City.
Brousse O, Martilli A, Zonato A, et al. · Bull Am Meteorol Soc 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.